IASIC Speaker Series Presents Cannabis Use and the Incidence of Psychotic Disorders

*Rescheduled from January 14*


The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed, organized, and guided by doctors.

Session: Cannabis Use and the Incidence of Psychotic Disorders: What should we consider before prescribing medicinal cannabis?
Presented By: Marta Diforti, MD, PhD
Date: Friday, February 25, 2022
Time: 11:00AM Eastern/8:00AM Pacific
Price: FREE

Cannabis is used daily by some 200 million people worldwide, and its use and potency have increased in many countries; for example, my group has shown that high potency types have taken over 96% of the London “street” market. Furthermore, the spread of laws legalizing cannabis for medicinal or recreational use has been accompanied by more relaxed attitudes towards cannabis. Cross-sectional and prospective epidemiological studies, as well as biological investigations, demonstrate a causal link between cannabis use and psychotic disorder, especially of a paranoid type. Furthermore, our research has shown a) a dose-response association with the highest odds of psychotic disorder in the heaviest cannabis users, b) high potency types carry the greatest risk for psychotic disorder, c) patterns of cannabis use have a major impact on the incidence of psychotic disorder across Europe. High potency cannabis types have high concentrations of delta-9-tetrahydrocannabinol (THC) and virtually no cannabidiol (CBD), which, in experimental studies of healthy volunteers ameliorates the psychotogenic effect of THC. A minority of cannabis users develop clinical psychosis, but it is unclear what proportion of heavy users develop minor psychotic symptoms and paranoia in particular. Therefore, in this talk, I shall present the above evidence and discuss how they might inform how and if we can move to safely prescribe cannabis for medicinal use.

Register For This FREE Session


View Upcoming Speakers

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

WADA Executive Committee Approves 2023 Prohibited List

On September 23, the World Anti-Doping Agency’s (WADA’s) Executive Committee (ExCo) held its second meeting of the year in Sydney, Australia. ExCo members, some of whom attended in person and others virtually, were updated on WADA’s progress on key priorities, took a number of decisions – the main ones being summarized below – and made

Doctors Inform Parents of Marijuana Use Linked to Youth Mental Health

Dr. Roneet Lev, with Scripps Hospital Emergency Room, wants to make sure parents and youth are making informed decisions and understand the risks. During Thursday’s event, doctors laid out the relationship between marijuana use and youth mental health. Lev warned that cannabis use is a suicide risk factor for people under the age of 25.

Changes in Traffic Crash Rates After Legalization of Marijuana

Legalization of the recreational use of marijuana was associated with a 6.5% increase in injury crash rates and a 2.3% increase in fatal crash rates, but the subsequent onset of retail marijuana sales did not elicit additional substantial changes. Thus, the combined effect of legalization and retail sales was a 5.8% increase in injury crash

Legalized Marijuana is a Global Warming Nightmare

Leaders in the Democratic Party are backing legislation to reduce carbon emissions. Some of them are also sponsoring bills that would expand the cannabis industry, ranging from the MORE Act to the Safe Banking Act and now the Cannabis Administration and Opportunity Act just introduced by Senate Majority Leader Chuck Schumer (D-NY). Co-sponsors have publicly

Scroll to Top